Forte Pharma, Reig Jofre’s nutritional supplements line, enters in Hong Kong and Macao
This operation is part of Reig Jofre's internationalization plan, by which 60% of company sales are now made outside Spain, with a target of 70% in 2019.
Forte Pharma, Reig Jofre’s nutritional supplements line, has recently entered Hong Kong and Macao through RS Lifestyle, a local partner, leader in the distribution of consumer products.
Watson’s drugstores, with more than 200 stores all around Hong Kong and Macao, has been the entry door for Forte Pharma in these markets, where the company has launched Vitality 4 from the energy range; and Turboslim Calorie Trapper, Turboslim Drink Peach tea and Turboslim Fat Redux 900 mg from slimming range.
Vitality 4, Turboslim Calorie Trapper, Turboslim Drink Peach tea and Turboslim Fat Redux 900 mg are among the top five products in Forte Pharma sales, and the first three with more than 10 years of recognized market position in its category. Turboslim Fat Redux was launched in 2014.
Following its integration in the pharmaceutical company Reig Jofre, Forte Pharma designed an expansion plan into new markets through agreements with local distributors. As a result of this strategy, in 2015 Forte Pharma initiated contacts in a dozen markets in Europe and Asia, which allowed as first achievement to formalize the entry into Hong Kong and Macao in the first months of 2016.
This operation is part of Reig Jofre's internationalization plan, by which 60% of company sales are now made outside Spain, with a target of 70% in 2019.
At present, marketing of Forte Pharma products is done mostly in Europe through its own sales network. In the coming years the company estimates a potential significant growth in markets where Forte Pharma is not yet present.
Forté Pharma products are organized into four ranges: slimming (54% of its total sales), energy (18%), beauty (17%) and health (11%). Revenues from the area of nutritional supplements and consumer healthcare, to which Forte Pharma belongs, amounted to 35 million euros in 2015, 22% of Reig Jofre total turnover, with a growth of 3% compared to 2014.
François Gaydier, Forte Pharma’s General Manager, said: "We hope that the entry into Hong Kong will help us to lay a solid foundation for further growth in the future via distribution agreements, since our goal is to launch other products in this market in the short term and expand our brand in other Asian countries."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance